Efficacy Test Of New HIV Vaccine Against Multiple Strains To Be Launched
Mohammad Ali (@ChaudhryMAli88) Published July 16, 2019 | 03:01 PM
The U.S. National Institutes of Health (NIH) and Janssen Pharmaceutical Companies of Johnson & Johnson announced Monday a plan to carry out an HIV vaccine efficacy trial in North America, South America and Europe
ISLAMABAD, (UrduPoint / Pakistan Point News - 16th Jul, 2019 ) :The U.S. National Institutes of Health (NIH) and Janssen Pharmaceutical Companies of Johnson & Johnson announced Monday a plan to carry out an HIV vaccine efficacy trial in North America, South America and Europe.
This Phase 3 efficacy study will enroll 3,800 HIV-negative men and transgender people aged 18 to 60 years who have sex with men and/or transgender people.
The study will evaluate an investigational vaccine called Mosaico based on "mosaic" immunogens, vaccine components comprising elements from multiple HIV subtypes, aiming to induce immune responses against a wide variety of global HIV strains.
"We are committed to developing a safe and effective preventive HIV vaccine suitable for the global populations most vulnerable to HIV acquisition," said Anthony S. Fauci, director of NIH's National Institute of Allergy and Infectious Diseases.
It is anticipated to open for enrollment in the United States later this year and the clinical research will also be done in Argentina, Brazil, Italy, Mexico, Peru, Poland and Spain, according to NIH.
"We are in the process of submitting regulatory applications to the respective Health Authorities/Ethics Committees," Corina Ramers-Verhoeven, a spokesperson with Janssen Pharmaceutical Companies, told Xinhua.
The vaccine candidate may work against multiple strains of the rapidly changing virus. Currently, there is no vaccine that could bring forth broadly neutralizing antibodies, the body's most effective protection against viruses.
Initial findings from Mosaico are expected in 2023, according to Janssen.
Mosaico will be the third HIV vaccine efficacy trial in progress worldwide. The other two are Imbokodo and HVTN 702, both being tested in African countries, according to NIH.
The World Health Organization has set a goal of ending the AIDS epidemic by 2030, and a vaccine is seen as a critical tool to achieve that goal.
Related Topics
Recent Stories
Tennis: ATP Barcelona Open results - 1st update
Swiatek's perfect 10 in Stuttgart as Vondrousova stuns Sabalenka
Arandu's roads closed due to flooding
Oil tanker catches fire in Islamabad’s Blue Area
Pakistan committed to ensure safety of foreign nationals: FO
Tennis: WTA Stuttgart results - 1st update
Four passengers injured as train hit an empty vehicle
Over- speeding bus crushed to death two bike riders
Turkey's Freedom Flotilla ready to set sail for Gaza
French teen dies from heart failure after knife attack near school
Iranians appear unfazed by Isfahan blasts
UAF celebrates Int'l Chinese Language Day
More Stories From Health
-
Rawalpindi woman gives birth to six babies
9 hours ago -
DC calls for intensive anti-polio drive in ICT
1 day ago -
World Hemophilia Day observed to underscore importance of providing comprehensive care
2 days ago -
Six in a family with heart on the 'right side'
2 days ago -
Diabetic disease increasing rapidly : Dr. Noor Elahi Memon
2 days ago -
World Hemophilia Day observed
2 days ago
-
ATC dismisses bail petition of doctor involved in illegal kidneys transplant
10 days ago -
Dr. Shehzad warns against deviation from WHO guidelines on anti-smoking
10 days ago -
Health activists express concerns over attempts to derail tobacco control
12 days ago -
UHS declares MBBS first prof, MS urology exam results
21 days ago -
Increased diagnostic testing for drug resistance
27 days ago -
IRD releases groundbreaking results of end TB programme
29 days ago